Analysis of Follicum now published

November 25, 2020

Analysis of Follicum now published

On 25 November 2020, Aktiespararna published their analysis of Follicum on their website. The analysis can also be read on Follicum’s webpage.

Read the analysis at Aktiespararna.se

For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: +46 (0)709 31 51 15
Email: info@follicum.com

About Follicum AB
Follicum AB (Spotlight: FOLLI) develops drugs based on tissue repairing peptides with potential use in a number of disease areas. The company’s most advanced drug candidate, FOL-005 for hair loss, is currently being evaluated in a Phase 2a study in collaboration with internationally renowned specialist clinics. In the field of diabetes, a project is being run aimed at protecting insulin-producing cells from damage and thus reducing the risk of complications. Based on promising preclinical results, preparations are underway for a Phase I study. Both projects have the potential to become so-called first-in-class drugs. For more information, visit www.follicum.com.

Open the analysis as pdf